Adjuvant chemotherapy with high-dose cyclophosphamide, etoposide and cisplatin intensification without progenitor cell support in breast cancer patients with ten or more involved nodes

5-Year results of a pilot trial

Alberto Ballestrero, Alessandra Rubagotti, Paola Stura, Fabio Ferrando, Domenico Amoroso, Michela Rinaldini, Piero Sismondi, Franco Genta, Mario Mesiti, Fulvio Brema, Franco Patrone, Francesco Boccardo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: The purpose of this study was to evaluate the clinical efficacy and tolerability of high-dose (HD) chemotherapy with growth factor support in primary breast cancer with extensive nodal involvement. Patients and Methods: Fifty-three patients with ten or more involved nodes were recruited and were given three cycles of standard-dose fluorouracil, epidoxorubicin and cyclophosphamide followed by one single course of high-dose CEP (cyclophosphamide, etoposide and cisplatin). No autologous progenitor support was used. Results: Five-year actuarial disease-free and overall survival were 40 and 60%, respectively. High-dose CEP required a median of 22 days of hospitalization and was associated with grade G3-G4 nausea and vomiting in two thirds of the cases. Hematological toxicity was comparable to that of high-dose therapies delivered with autologous progenitor support. No therapy-related mortality was observed. Conclusions: The efficacy of treatment was comparable to the best results of conventional therapy, with only a trend for improved survival. High-dose CEP was feasible with acceptable toxicity. Although this regimen does not require stem cell harvesting and storage, it requires clinical support comparable to autotransplantation procedures and side effects are not so manageable to recommend its use outside specialized units.

Original languageEnglish
Pages (from-to)221-227
Number of pages7
JournalOncology
Volume60
Issue number3
DOIs
Publication statusPublished - 2001

Fingerprint

Etoposide
Adjuvant Chemotherapy
Cyclophosphamide
Cisplatin
Stem Cells
Breast Neoplasms
Autologous Transplantation
Fluorouracil
Nausea
Disease-Free Survival
Vomiting
Intercellular Signaling Peptides and Proteins
Hospitalization
Therapeutics
Drug Therapy
Survival
Mortality

Keywords

  • Breast cancer, primary
  • High-dose chemotherapy
  • High-risk breast cancer
  • Irradiation
  • Progenitor cell support

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Adjuvant chemotherapy with high-dose cyclophosphamide, etoposide and cisplatin intensification without progenitor cell support in breast cancer patients with ten or more involved nodes : 5-Year results of a pilot trial. / Ballestrero, Alberto; Rubagotti, Alessandra; Stura, Paola; Ferrando, Fabio; Amoroso, Domenico; Rinaldini, Michela; Sismondi, Piero; Genta, Franco; Mesiti, Mario; Brema, Fulvio; Patrone, Franco; Boccardo, Francesco.

In: Oncology, Vol. 60, No. 3, 2001, p. 221-227.

Research output: Contribution to journalArticle

Ballestrero, Alberto ; Rubagotti, Alessandra ; Stura, Paola ; Ferrando, Fabio ; Amoroso, Domenico ; Rinaldini, Michela ; Sismondi, Piero ; Genta, Franco ; Mesiti, Mario ; Brema, Fulvio ; Patrone, Franco ; Boccardo, Francesco. / Adjuvant chemotherapy with high-dose cyclophosphamide, etoposide and cisplatin intensification without progenitor cell support in breast cancer patients with ten or more involved nodes : 5-Year results of a pilot trial. In: Oncology. 2001 ; Vol. 60, No. 3. pp. 221-227.
@article{8b69646a0ffa4a0aac70a97de21e3953,
title = "Adjuvant chemotherapy with high-dose cyclophosphamide, etoposide and cisplatin intensification without progenitor cell support in breast cancer patients with ten or more involved nodes: 5-Year results of a pilot trial",
abstract = "Objectives: The purpose of this study was to evaluate the clinical efficacy and tolerability of high-dose (HD) chemotherapy with growth factor support in primary breast cancer with extensive nodal involvement. Patients and Methods: Fifty-three patients with ten or more involved nodes were recruited and were given three cycles of standard-dose fluorouracil, epidoxorubicin and cyclophosphamide followed by one single course of high-dose CEP (cyclophosphamide, etoposide and cisplatin). No autologous progenitor support was used. Results: Five-year actuarial disease-free and overall survival were 40 and 60{\%}, respectively. High-dose CEP required a median of 22 days of hospitalization and was associated with grade G3-G4 nausea and vomiting in two thirds of the cases. Hematological toxicity was comparable to that of high-dose therapies delivered with autologous progenitor support. No therapy-related mortality was observed. Conclusions: The efficacy of treatment was comparable to the best results of conventional therapy, with only a trend for improved survival. High-dose CEP was feasible with acceptable toxicity. Although this regimen does not require stem cell harvesting and storage, it requires clinical support comparable to autotransplantation procedures and side effects are not so manageable to recommend its use outside specialized units.",
keywords = "Breast cancer, primary, High-dose chemotherapy, High-risk breast cancer, Irradiation, Progenitor cell support",
author = "Alberto Ballestrero and Alessandra Rubagotti and Paola Stura and Fabio Ferrando and Domenico Amoroso and Michela Rinaldini and Piero Sismondi and Franco Genta and Mario Mesiti and Fulvio Brema and Franco Patrone and Francesco Boccardo",
year = "2001",
doi = "10.1159/000055322",
language = "English",
volume = "60",
pages = "221--227",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "3",

}

TY - JOUR

T1 - Adjuvant chemotherapy with high-dose cyclophosphamide, etoposide and cisplatin intensification without progenitor cell support in breast cancer patients with ten or more involved nodes

T2 - 5-Year results of a pilot trial

AU - Ballestrero, Alberto

AU - Rubagotti, Alessandra

AU - Stura, Paola

AU - Ferrando, Fabio

AU - Amoroso, Domenico

AU - Rinaldini, Michela

AU - Sismondi, Piero

AU - Genta, Franco

AU - Mesiti, Mario

AU - Brema, Fulvio

AU - Patrone, Franco

AU - Boccardo, Francesco

PY - 2001

Y1 - 2001

N2 - Objectives: The purpose of this study was to evaluate the clinical efficacy and tolerability of high-dose (HD) chemotherapy with growth factor support in primary breast cancer with extensive nodal involvement. Patients and Methods: Fifty-three patients with ten or more involved nodes were recruited and were given three cycles of standard-dose fluorouracil, epidoxorubicin and cyclophosphamide followed by one single course of high-dose CEP (cyclophosphamide, etoposide and cisplatin). No autologous progenitor support was used. Results: Five-year actuarial disease-free and overall survival were 40 and 60%, respectively. High-dose CEP required a median of 22 days of hospitalization and was associated with grade G3-G4 nausea and vomiting in two thirds of the cases. Hematological toxicity was comparable to that of high-dose therapies delivered with autologous progenitor support. No therapy-related mortality was observed. Conclusions: The efficacy of treatment was comparable to the best results of conventional therapy, with only a trend for improved survival. High-dose CEP was feasible with acceptable toxicity. Although this regimen does not require stem cell harvesting and storage, it requires clinical support comparable to autotransplantation procedures and side effects are not so manageable to recommend its use outside specialized units.

AB - Objectives: The purpose of this study was to evaluate the clinical efficacy and tolerability of high-dose (HD) chemotherapy with growth factor support in primary breast cancer with extensive nodal involvement. Patients and Methods: Fifty-three patients with ten or more involved nodes were recruited and were given three cycles of standard-dose fluorouracil, epidoxorubicin and cyclophosphamide followed by one single course of high-dose CEP (cyclophosphamide, etoposide and cisplatin). No autologous progenitor support was used. Results: Five-year actuarial disease-free and overall survival were 40 and 60%, respectively. High-dose CEP required a median of 22 days of hospitalization and was associated with grade G3-G4 nausea and vomiting in two thirds of the cases. Hematological toxicity was comparable to that of high-dose therapies delivered with autologous progenitor support. No therapy-related mortality was observed. Conclusions: The efficacy of treatment was comparable to the best results of conventional therapy, with only a trend for improved survival. High-dose CEP was feasible with acceptable toxicity. Although this regimen does not require stem cell harvesting and storage, it requires clinical support comparable to autotransplantation procedures and side effects are not so manageable to recommend its use outside specialized units.

KW - Breast cancer, primary

KW - High-dose chemotherapy

KW - High-risk breast cancer

KW - Irradiation

KW - Progenitor cell support

UR - http://www.scopus.com/inward/record.url?scp=17744373449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17744373449&partnerID=8YFLogxK

U2 - 10.1159/000055322

DO - 10.1159/000055322

M3 - Article

VL - 60

SP - 221

EP - 227

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3

ER -